The acquisition will include PBMI’s trademarks, conference, website, education, and membership assets.
MJH Life Sciences, a medical media company based in Cranbury, NJ, and the owner of Pharmaceutical Technology and BioPharm International, announced on April 2, 2020 that it has acquired the Pharmacy Benefit Management Institute (PBMI), a Plano, TX-based provider of research and education for the pharmacy benefit market, from Pharmaceutical Strategies Group (PSG).
According to a company press release, the acquisition will include PBMI’s trademarks, conference, website, education, and membership assets. Additionally, all current and future research and analytics projects will remain with PSG under the leadership of Sharon Frazee, PhD, senior vice-president of Research and Data Innovation at PBMI.
“Credible information is critical to healthcare professionals during this global pandemic, and education about how it will impact drug benefit management is vital,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences, in the press release. “For 25 years, PBMI’s annual meeting has been a driver of change within the marketplace, and as part of our Managed Markets Network, we look forward to growing the conference to make an even bigger impact in the field of managed care.”
“After careful consideration, we have decided to give PBMI a new home where it can continue its mission and prosper for many years to come,” added Dave Borden, CEO of PSG, in the press release. “MJH Life Sciences is a global business with significant resources and experience in the area of conference management and education, and we are confident the organization will enable PBMI to further its mission and reach new heights. We look forward to continuing our relationship with PBMI and hope to see our friends, partners, and colleagues at PBMI events for many years to come.”
Source: MJH Life Sciences
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.